The invention relates to a bevantolol hydrochloride orally disintegrating tablet, which consists of a therapeutically effective amount of bevantolol hydrochloride, citric acid, sodium bicarbonate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and other pharmaceutically acceptable pharmaceutical excipients. The orally disintegrating tablet can be prepared by mixing the bevantolol hydrochloride, the citric acid, the microcrystalline cellulose and partial low-substituted hydroxypropyl cellulose evenly, taking 70 percent ethanol as an adhesive for pelletization, and then adding a residual amount of the low-substituted hydroxypropyl cellulose and other pharmaceutical excipients. The bevantolol hydrochloride orally disintegrating tablet can effectively solve the problem oflow bioavailability of ordinary tablets due to first pass effect.